4D Molecular Therapeutics has posted 60-week data on a gene therapy, providing evidence of durability in diabetic macular edema (DME) and sending its stock up more than 40% in premarket trading. The ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results